29274-18-8

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate is used as a potential drug candidate for [specific application reason, if available] due to its pharmacological properties. Its complex molecular structure and the presence of functional groups such as the ethyl and carboxylate groups may contribute to its potential therapeutic effects.
[If there are specific applications in different therapeutic areas or diseases, they can be listed separately as follows:]
Used in [Specific Therapeutic Area or Disease] Treatment:
Ethyl 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate is used as a [specific application type, e.g., therapeutic agent, drug precursor, etc.] for [specific application reason, e.g., targeting a particular biological pathway, enzyme, or receptor involved in the disease process].
[Note: The specific application reason and the role of ethyl 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate in the treatment of a particular therapeutic area or disease would depend on the results of further research and investigation.]

Upstream product

• 29274-17-7 diethyl 2-((1H-pyrazol-5-ylamino)methylene)malonate 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 1820-80-0 3-aminopyrazole 

Downstream Products

• 197367-75-2 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid 
• 877173-84-7 3-bromo-7-chloropyrazolo[1,5-a]pyrimidine 
• 58347-49-2 7-chloropyrazolo[1,5-a]pyrirnidine 
• 1161024-91-4 N-(2,4-di-tert-butyl-5-hydroxyphenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide 
• 29274-23-5 4,7-dihydropyrazolo<1,5-a>pyrimidin-7-one 

Relevant academic research and scientific papers

Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors

Aldose reductase (AKR1B1), the key enzyme of the polyol pathway, plays a crucial role in the development of long-term complications affecting diabetic patients. Nevertheless, the expedience of inhibiting this enzyme to treat diabetic complications has fai

Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure-Activity Relationship Study on Tofacitinib Bioisosteres

The Janus kinases (JAKs) are a family of cytosolic tyrosine kinases crucially involved in cytokine signaling. JAKs have been demonstrated to be valid targets in the treatment of inflammatory and myeloproliferative disorders, and two inhibitors, tofacitinib and ruxolitinib, recently received their marketing authorization. Despite this success, selectivity within the JAK family remains a major issue. Both approved compounds share a common 7H-pyrrolo[2,3-d]pyrimidine hinge binding motif, and little is known about modifications tolerated at this heterocyclic core. In the current study, a library of tofacitinib bioisosteres was prepared and tested against JAK3. The compounds possessed the tofacitinib piperidinyl side chain, whereas the hinge binding motif was replaced by a variety of heterocycles mimicking its pharmacophore. In view of the promising expectations obtained from molecular modeling, most of the compounds proved to be poorly active. However, strategies for restoring activity within this series of novel chemotypes were discovered and crucial structure-activity relationships were deduced. The compounds presented may serve as starting point for developing novel JAK inhibitors and as a valuable training set for in silico models.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof of formula (I), including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention

Synthesis of pyrazolo[1,5-α]pyrimidinone regioisomers

(Chemical Equation Presented) This work describes two distinct routes to prepare pyrazolo-[1,5-α]pyrimidin-7-ones and two distinct routes to prepare pyrazolo[1,5-α]pyrimidin-5-ones. Use of 1,3-dimethyluracil as the electrophile in the preparation of the p

4-Quinolone derivatives: High-affinity ligands at the benzodiazepine site of brain GABAA receptors. Synthesis, pharmacology, and pharmacophore modeling

The 3-ethoxycarbonyl-4-quinolone compound 1 has previously been identified via a database search as an interesting lead compound for ligand binding at the benzodiazepine site of GABAA receptors (Kahnberg et al. J. Mol. Graphics Modelling 2004, 23, 253-261). Pharmacophore-guided optimization of this lead compound yielded a number of high-affinity ligands for the benzodiazepine site including compounds 20 and 23-25 displaying sub-nanomolar affinities. A few of the compounds have been tested on the α1β 2γ2S and α3β 2γ2S GABAA receptor subtypes, and two of the compounds (5 and 19) display selectivity for α1-versus α3-containing receptors by a factor of 22 and 27, respectively. This selectivity for α1β2γ2S is in the same range as that for the well-known α1 subunit selective compound zolpidem.